Hormone replacement therapy: The risks and benefits of treatment

Journal of the Royal College of Physicians of Edinburgh

Volumn 39, Issue 4, 2009, Pages 324-326

  Hardie, C ^a   Bain, C ^a   Walters, M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Hormone replacement therapy; Menopause; Oestrogen

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN;

ATHEROMA; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG SAFETY; ESTROGEN THERAPY; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MONOTHERAPY; OSTEOARTHRITIS; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SHORT SURVEY; STROKE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 74249120934     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2009.408     Document Type: Short Survey

References (21)

1. Hill K. The demography of menopause. Maturitas 1996; 23:113-27. doi:10.1016/0378-5122(95)00968-X
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33. doi:10.1001/jama.288.3.321
3. Grady D, Herrington D, Bittner V et al., for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:49-57. doi:10.1001/ jama.288.1.49
4. Hulley S, Purberg C, Barrett-Connor E et al., for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58-66. doi:10.1001/jama.288.1.58
5. Beral V, Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362:419-27. doi:10.1016/S0140-6736(03)14596-5
6. Pines A, Sturdee W, Birkhauser MH et al., for the International Menopause Society. HRT in the early menopause: scientific evidence and common perceptions. Climacteric 2008; 11:267-72. doi:10.1080/13697130802226866
7. Kim N, Gross C, Curtis J et al. The impact of clinical trials on the use of hormone replacement therapy: a population-based study. J Gen Intern Med 2005; 20:1026-31. doi:10.1111/j.1525-1497.2005.0221.x
8. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-77. doi:10.1001/ jama.297.13.1465
9. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356:2591-602. doi:10.1056/NEJMoa071513
10. Grodstein F, Manson JE, Stampfer J et al. Postmenopausal hormone therapy and stroke. The role of time since menopause and age of initiation of hormone therapy. Arch Intern Med 2008; 168:861-6. doi:10.1001/archinte.168.8.861
11. Jackson RD, Wactawski-Wende J, LaCroiz AZ et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res 2006; 21:817-28. doi:10.1359/jbmr.060312
12. Gambacciani M, Ciaponi M, Genazzani AR. The HRT misuse and osteoporosis epidemic: a possible future scenario. Climacteric 2007; 10:273-5. doi:10.1080/13697130701511277
13. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289:3243-53. doi:10.1001/jama.289.24.3243
14. Stefanick ML, Anderson GL, Margolis KL et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295:1647-57. doi:10.1001/jama.295.14. 1647
15. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369:1703-10. doi:10.1016/S0140-6736(07)60534-0
16. Anderson GL, Judd HL, Kaunitz AM et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA 2003; 290:1739-48. doi:10.1001/jama.290.13.1739
17. Cushman M, Kuller LH, Prentice et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573-80. doi:10.1001/ jama.292.13.1573
18. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-5. doi:10.1161/ CIRCULATIONAHA.106.642280
19. Scarabin PY, Oger E, Plu-Bureau G et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362:428-32. doi:10.1016/ S0140-6736(03)14066-4
20. Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839-54. doi:10.1056/NEJMoa030311
21. Welton AJ, Vickers MR, Kim J et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008; 337:a1190. doi:10.1136/bmj.a1190